Esophageal adenocarcinoma (EAC) is highly aggressive malignancy that frequently develops from Barrett's esophagus (BE), a premalignant pathologic change occurring in the lower end of the esophagus. MicroRNAs (miRNAs) are small, non-coding RNAs that function as posttranscriptional regulators of gene expression and were repeatedly proved to play key roles in pathogenesis of BE as well as EAC. In our study, we used Affymetrix GeneChip miRNA arrays to obtain miRNA expression profiles in total of 119 tissue samples [24 normal esophageal mucosa (EM), 60 BE and 35 EAC]. We identified a number of miRNAs, that showed altered expression progressively in sequence EM, BE and EAC, including for instance miR-21, miR-25, miR-194 and miR-196a with increasing levels (P < 0.0015) and miR-203, miR-205, miR-210 and miR-378 with decreasing levels (P < 0.0001). The subsequent analysis revealed four diagnostic miRNA signatures enabling to distinguish EM and BE [12 miRNAs, area under curve (AUC) = 0.971], EM and EAC (13 miRNAs, AUC = 1.0), BE without and BE with dysplasia (21 miRNAs, AUC = 0.856) and BE without dysplastic changes and BE with dysplasia together with EAC (2 miRNAs, AUC = 0.886). We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.
Introduction
Barrett's esophagus (BE) is an acquired condition related to chronic and severe gastroesophageal reflux in which the normal epithelium of the distal esophagus is replaced by a metaplastic intestinal epithelium (1) . The incidence of BE increases with age and may be present in 1-2% of general population after the age of 60 years (1, 2) . Patients with BE show a weak lower esophageal sphincter pressure, high rates of both acid and duodenogastroesophageal reflux and defective esophageal peristalsis (3) . BE is associated with a 0.5% risk per year of developing esophageal adenocarcinoma (EAC), whereas dysplasia is currently used as the main biomarker to identify BE patients at high risk for developing EAC (1, 4) .
It is generally believed that the progression of BE follows a series of histologic changes: non-dysplastic Barrett's intestinal metaplasia, low-grade dysplasia (LGD), high-grade dysplasia (HGD) and ultimately, adenocarcinoma (1, 4) . The malignant progression rate of BE varies depending on the presence of dysplasia in BE tissues, and the progression rate of non-dysplastic Barrett's metaplasia and LGD is much lower than that of HGD (1, 4, 5) . The risk of developing EAC in patients with HGD may be as high as 10% per patient year (4, 5) .
However, the grading of dysplasia is subjective resulting in substantial interobserver variations among pathologists on the degrees of dysplasia (6) . There is therefore an ongoing need to develop independent objective biomarkers to predict malignant progression that may complement and augment pathologic grading and improve risk stratification among patients with BE, allowing cost-effective surveillance, screening and treatment of patients with BE (7) .
Today, one of the most progressive approaches for molecular characterization of tumors is based on microRNAs (miRNA) expression profiling. miRNAs comprise a family of short, 18-25 nucleotides long, non-coding RNAs, which regulate gene expression posttranscriptionally, on the messenger RNA (mRNA) level. The ability of miRNAs to inhibit translation of oncogenes and tumor suppressors implies their involvement in carcinogenesis (8) (9) (10) . Analysis of miRNA expression profiles is frequently used for molecular classification of cancer, analogically to DNA microarrays and mRNA profiling (11) , whereas in several cases miRNA profiling shows superiority to mRNA profiling (12) . From the analytical perspective, it is important to note that, due to their small size, miRNAs are subjected relatively less to degradation than mRNAs and, thus, are applicable for formalin-fixed paraffin-embedded (FFPE) tissue analyses (13, 14) .
Several studies have focused on miRNAs' significance in BE and EAC (15) . These papers described the potential of miRNA profiles to distinguish BE tissue from esophageal mucosa (EM) and EAC (16) (17) (18) (19) (20) (21) (22) or to identify BE patients at high risk of progression to EAC (23) (24) (25) (26) . The main weakness of these studies is low number of patients in exploratory phase with consequent low performance in validation phase and low level of consistency between independent studies (15) . Therefore, BE-and EAC-associated miRNA profiles described till now cannot be considered conclusive.
The aims of this study were to reveal BE and EAC miRNA expression profiles, to identify miRNAs progressively deregulated in sequential carcinogenesis EM-BE-EAC and to identify miRNA signatures enabling classification of EM, BE and EAC samples with moderate accuracy leading to potential diagnostic usage and improvement of risk stratification of BE patients.
Materials and methods

Patients
A total of 119 tissue samples [24 normal (uninvolved) mucosa samples from the distal esophagus of BE patients, 60 BE and 35 EAC] were included in the retrospective one-center study (Department of Gastroenterology, University Hospital, Olomouc, Czech Republic). All BE tissues were from patients, who did not have diagnosis of cancer, among which were 33 Barrett's metaplasia without dysplasia, 21 BE with LGD and 6 BE with HGD. Changes in esophagus were evaluated accordingly to Prague C and M criteria and histological examination of biopsy samples. Clinicopathologic characteristics of BE and EAC patients are summarized in Table 1 . All tissue specimens were reviewed for histologic reading by at least one experienced gastrointestinal pathologist before total RNA extraction. Informed consent approved by the local Ethical Commission was obtained from each patient before the treatment. Clinical data were retrieved from the hospital's patient records.
Tissue sample preparation and nucleic acid extraction
The tissue samples were fixed in formalin immediately after extraction. All samples were deparaffinized and RNA extraction was carried out by use of mirVana miRNA Isolation Kit (Ambion, Austin, TX) accordingly to the manufacturer's instructions. Concentration and purity of RNA were determined spectrophotometrically by measuring its optical density 
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miRNA microarray analysis
To assess miRNA expression in FFPE tissue samples, total RNA, including a fraction of small RNA, was used and analyzed with Affymetrix GeneChip miRNA 3.0 arrays (Affymetrix, Santa Clara, CA) containing 5607 probe sets for human small RNAs. Out of these probe sets the 1733 probe sets of human mature miRNAs were filtered. These probe sets guarantee 100% coverage of all human mature miRNAs in miRBase v.17 (April 2011). Probe sets that were deleted in a more recent version of miRBase were excluded for analysis. All steps of the procedure were performed according to the Affymetrix standardized protocol for miRNA 3.0 arrays. Briefly, 130 ng of total RNA was poly-A tailed, followed by ligation of the biotin-labeled molecule, using the FlashTag Biotin HSR RNA Labeling Kit (Genisphere, Hatfield, PA). A hybridization cocktail was added to the biotin-labeled RNA sample and heated to 99°C for 5 min and then to 45°C for another 5 min. This mixture was injected into an Affymetrix miRNA 3.0 array and hybridization was performed under rotation at 48°C for 16 h. After washing and staining steps using the Affymetrix Fluidics Station, the arrays were scanned on the Affymetrix 3000 GeneScanner. Intensity values for each probe cell (.cel file) were calculated using Affymetrix GeneChip Command Console. Quality control of the microarray was performed with the Affymetrix miRNA QC Tool, version 1.1.1.0.
Microarray expression data analysis
The Affymetrix raw data (.cel files) were normalized using the robust multichip average algorithm from 'oligo' Bioconductor package (27) in R version 3.0.1 (28) . The LIMMA package (29) was used to identify differentially expressed miRNA probe sets between different groups of patients. Obtained P values were adjusted for multiple testing using the Benjamini-Hochberg correction. Annotations of miRNA probe sets were derived from the Sanger miRBase database v.20 (June 2013, http://mirbase. org). Combinations of candidate miRNAs enabling to distinguish different sample types with the highest predictive power were reached by logistic regression. To generate unbiased training and testing sets, leave-one-out cross-validation procedure was used. With this methodology, each data point is tested with a classifier trained using all of the remaining data points. Receiver operating characteristic curves were plotted with the 'ROCR' R package (30) .
Results
miRNAs differentially expressed between EM, BE without dysplasia, BE with dysplasia (LGD and HGD) and EAC
We used miRNA arrays to obtain global miRNA expression profiles in total of 119 tissue samples (24 EM, 33 BE, 21 BE-LGD, 6 BE-HGD and 35 EAC). LIMMA and HCL analysis revealed 73 significantly upregulated and 70 downregulated miRNAs in BE tissue when compared with EM (P < 0.001) (see Supplementary  Table S1 , available at Carcinogenesis Online). Among them, 13 miRNAs showed P value <10 −8 and were able to discriminate BE and EM samples with high accuracy ( Figure 1A ). Highly specific miRNA expression profile was identified also when EAC was compared with EM tissue. By use of same method we reached 51 upregulated miRNAs and 40 downregulated miRNAs in EAC tissue (P < 0.0001) (see Supplementary Table S2 , available at Carcinogenesis Online). Among them, 38 miRNAs showed P value <10 −5 and were able to discriminate EAC and EM samples with high accuracy ( Figure 1B) . miRNAs with significantly different expression were identified also when BE without dysplasia was compared with EAC. In EAC tissue, 55 miRNAs were upregulated and 24 miRNAs downregulated (P < 0.001) (see Supplementary  Table S3 , available at Carcinogenesis Online). Among them, 22 miRNAs showed P < 0.0001 and were able to discriminate BE and EAC samples with high accuracy ( Figure 1C) . Finally, miRNAs differentially expressed between BE with LGD or HGD and EAC were identified, whereas 25 miRNAs were upregulated and 42 miRNAs were downregulated in dysplastic BE (P < 0.001) (see Supplementary Table S4 , available at Carcinogenesis Online). Among them, 22 miRNAs showed P < 0.0001 and were able to discriminate BE and EAC samples with high accuracy ( Figure 1D ). Among them, 15 miRNAs showed P < 0.0005 and were able to discriminate dysplastic BE and EAC samples with high accuracy ( Figure 1D ).
miRNAs showing altered expression progressively in sequence EM, BE and EAC
The most biologically relevant miRNAs specifically involved in BE progression are likely those with progressively altered expression along the different stages. Table 2 shows the miRNAs with progressively altered expression in sequence EM, BE and EAC, which are likely to act as oncogenes or tumor suppressors and are probably involved in esophageal carcinogenesis. Among these miRNAs, 11 indicated progressively decreasing levels (P < 0.0001) and 16 progressively increasing expression levels (P < 0.0015) in EM, BE and EAC tissue. Some of these miRNAs are well known in esophageal cancer to play role as oncogenic miRNA like miR-21, miR-25, miR-196a and miR-181a; some of them are known to act as tumor suppressors such as miR-23b, miR-27b, miR-203 and miR-205. Another set of miRNAs was observed to be progressively altered in BE and EAC for the first time, for instance miR-149, miR-744 or miR-503 (summarized in Table 2 ). There were also five miRNAs, which were upregulated in BE and had lower expression in EAC than in BE tissues, although still higher than normal epithelium tissues (Table 3) .
Unique miRNA signatures enabling classification of different subgroups of BE and EAC patients
We examined which combination of miRNAs among the candidate miRNAs (50 miRNAs with the most significant differences between groups) could distinguish the different sample types with the highest predictive power by logistic regression. Leave-one-out cross-validation was used to avoid overfitting of the data. Application of this approach revealed four diagnostic miRNA signatures (characterized in Table 4 ) enabling to distinguish EM and BE [12 miRNAs; 94% sensitivity (SN), 100% specificity (SP) and area under curve (AUC) = 0.971; Figure 2A ], EM and EAC (13 miRNAs, 100% SN, 100% SP and AUC = 1.0; Figure 2B ), BE without and BE with dysplasia (21 miRNAs; 82% SN, 82% SP and AUC = 0.856; Figure 2C ) and BE without dysplastic changes and BE with dysplasia together with EAC (2 miRNAs; 79% SN, 84% SP and AUC = 0.886; Figure 2D ). Altogether, we have identified four tissue miRNA signatures that may serve as novel diagnostic biomarkers to discriminate between EM, non-dysplastic BE, BE-LGD, BE-HGD and EAC.
Discussion
The phenotypic shift from BE to EAC involves a well-established sequence of histological lesions. Although the molecular basis of BE progression to EAC has been widely studied (1-4) , molecular profiling of each of these premalignant changes has produced inconsistent results. Histological classification based on FFPE tissue samples is a prerequisite for patients' risk stratification, but high-throughput technologies based on transcriptome analysis are only partially applicable to FFPE tissue samples due to mRNA degradation and this significantly limits any efforts to associate molecular with histological profiles consistently (13) . miRNA molecules are stable in FFPE tissue samples and miRNA testing in previously histologically assessed lesions may consistently associate with any target phenotype with its molecular profile (20) . By using FFPE tissues, aberrant miRNA expression patterns have been described in a variety malignancies and have been shown to represent powerful potential as diagnostic, prognostic and therapeutic tools in a wide range of cancer indications (9, 10, 13, 14) .
This study provides the most comprehensive list of miRNA expressions in BE and EAC to date. A total of 1733 mature miRNAs have been profiled by microarray approach in 119 FFPE tissue samples of EM, BE and EAC. There is only one comparable study on the topic, published by Wu et al. (7) , based on quantitative reverse transcription-PCR profiling of 754 miRNAs in 105 tissue samples of EM, BE and EAC. Very importantly, there is significant overlap between miRNA profiles identified in both studies indicating accuracy of the results even if they were reached by different methodical approaches. Moreover, a number of the well-known oncogenic miRNAs (e.g. miR-21, miR-25, miR-205) and tumor suppressor miRNAs (e.g. miR-27b, miR-23b) were confirmed in our study.
We assessed whether differential expression of miRNAs exists between EM and BE tissue and identified miRNA expression profile specific for BE characterized by 73 upregulated and 70 downregulated miRNAs. Although we observed lower ratio of upregulated/downregulated miRNAs than Wu et al. (7) in his profiling study (1.0 versus 9.3), there was a high level of concordance in BE-specific miRNA signatures, when our data were compared with results of this and other previous studies (15) (16) (17) (18) (19) (20) (21) (22) . For instance, miR-21, miR-27b, miR-99a, miR-143, miR-145, miR146a, miR-192, miR-194, miR-203, miR-205 and miR-210 identified in our study as the top significant miRNAs were observed to be deregulated in at least two other independent studies (15) (16) (17) (18) (19) (20) (21) (22) hsa-miR-145_st
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hsa-miR- 28-5p_st   80_op  103  19  7  84  44  83  5  64  156  159  43  59  15  78  81  60  63  56  74  54_op  24  62  1  10  89  26  36  34  6  41  23  65  21  73  90  72_op  76_op  110  108  113  99  95  93  115  111  92  107  75  86  82  105  85  102  97  109  91  94  96  101  100 miRNAs among the most significantly deregulated miRNAs were observed in our study for the first time (miR-149, miR-214, miR-617, miR-625, miR-214, miR-708) and present interesting targets for further investigations in BE. Similar level of accordance with previous profiling studies was reached also when EAC-specific miRNA expression profiles were analyzed (15) (16) (17) (18) (19) (20) (21) (22) . Interestingly, significant proportion of miRNAs (60%) identified to be deregulated in EAC (Supplementary Table S2 , available at Carcinogenesis Online, Figure 1C and D) was altered also in BE tissue analogically to results reached by Yang et al. (17) and Wu et al. (7) indicating strong molecular link between different stages in sequential model of EAC carcinogenesis. Although we identified profile of miRNAs differentially expressed between BE and EAC tissues, significance of these changes was not as high as expected, which is probably caused by the fact, that miRNA profiles of BE and EAC are very similar when compared with EM. It seems that these miRNAs are indicative for tissue metaplasia rather than being associated with progression to carcinoma. The most biologically relevant miRNAs involved in BE progression are likely those with progressively altered expression in EM-BE-EAC sequence (summarized in Table 2 ). Several of these miRNAs were shown previously to be associated with BE progression to dysplastic stages and EAC (for instance oncogenic miR-21, miR-25, miR-196a and miR-181a, tumor suppressive miR-23b, miR-27b, miR-203 and miR-205) (23) (24) (25) , some of them (miR-192, miR-194, miR-196a and miR-196b) enabled risk assessment and prediction of BE progression as described in recent study of Revilla-Nuin et al. (26) . Several miRNAs were observed to be associated with BE progression for the first time, for instance miR-149, miR-744 or miR-503 (Table 2 ). There were also five (Table 3) . From these, miR-375 previously associated with epithelial-mesenchymal transition and regulation of IGF signaling was also proved to be downregulated in EAC when compared with BE indicating its potential usage as biomarker for early detection of BE progression (25) . miR-200b was repeatedly linked to epithelial-mesenchymal transition and acquiring of invasive abilities for cancer cells (31) . Finally, we examined by logistic regression which combination of candidate miRNAs could distinguish the tissues of different histology with the highest predictive power. We revealed four diagnostic miRNA signatures (characterized in Table 4 ) enabling to distinguish BE without and BE with dysplasia and EAC with a high level of accuracy (Table 4) . Implementation of this diagnostic miRNA signatures, especially of the 2-miRNA signature based on miR-375 and miR-93 analysis, brings possibility of reasonable and mainly objective detection of dysplastic changes or carcinoma cells in widely available FFPE tissue from BE biopsies with high SN and SP (AUC = 0.89). However, there are some limitations in our study. This is a cross-sectional study in which BE and EAC samples were not paired, but from separate individuals. To prove that these biomarkers predict EAC progression in patients with BE, prospective follow-up study is needed, whereas the low progression rate and long latency period make prospective study very difficult. Our sample size is sufficient for cross-comparison of different histologic tissues; however, the sample size is not sufficient to conduct stratified analyses and identify miRNAs associated with smoking, obesity, BE extent, survival and other clinical variables. Further validation of the newly identified markers in larger independent populations is necessary.
In conclusion, our findings strongly support the role of miRNAs in BE and sequential model of EAC carcinogenesis. We have confirmed many previously reported miRNA biomarkers and identified additional new miRNAs that were differentially expressed at various stages of BE and EAC. The results of this investigation may open avenues for more in-depth understanding of the biology of tumor transformation in esophageal cancer. Examination of BE tissue from biopsies for presence of identified BE-LGD-, BE-HGD-and EAC-specific miRNA signatures may complement and augment pathologic grading and improve risk stratification among patients with BE, allowing cost-effective surveillance, screening and treatment of BE patients.
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